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Widespread adoption of the antiplatelet agents into everyday
clinical practice has revolutionised contemporary care of the
cardiovascular patient. Currently available antiplatelet
agents include aspirin, dipyridamole, thienopyridines (ticlo-
pidine and clopidogrel) and glycoprotein IIb/IIIa receptor
antagonists.13 They are used for the management of patients
with acute coronary syndromes, secondary prevention of
ischaemic events to the heart, brain and limbs.8,13
Clopidogrel is used for a wide variety of acute and chronic
cardiovascular conditions.8 It inhibits ADP-induced platelet
aggregation by irreversibly changing one of the platelet
receptors of ADP.8,13 It has been noted that patients on
low dose aspirin have increased bleeding tendency, but this
is not a major problem for most types of surgery. Data about
clopidogrel and bleeding is scantier.8,13,14 There are no
published reports in the English literature of patients on
clopidogrel undergoing emergency orthopaedic surgery.
Traditionally, clopidogrel is stopped for five to seven days
before surgery if possible. This allows the bone marrow to
restore the platelet pool to sufficient levels to achieve
satisfactory haemostasis.8,11,13,14 There is no wholly* Corresponding author at: 7 Glebe Road, Solihull, West Midlands,
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Open access under the Elsevier OA license.accepted test, including the bleeding time, which will reli-
ably guide antiplatelet therapy. However, the withdrawal of
antiplatelet therapy and the prothrombotic state in the
postoperative phase can increase the risk of cardiovascular
events.11 Patients with coronary stents, especially those
which are drug eluting, have an increased risk of stent
thrombosis if clopidogrel is stopped within a year of cardiac
intervention.8 No clear cut guidelines exist for the timing of
surgery in trauma patients on clopidogrel who will benefit
from early intervention. We describe our experience of five
patients admitted over a four-week period who underwent
hip fracture surgery two days of stopping clopidogrel.
Cases 1, 2, 3 and 4
They all had uneventful hip fracture surgery two days after
omitting the clopidogrel. The perioperative period and rele-
vant past medical history is summarised in Table 1. None had
a wound dehiscence, haematoma and infection or needed
blood products. They were all discharged to the rehabilita-
tion ward and went home without any complications.
Case 5
An 80-year-old man was admitted with an intracapsular neck
of femur fracture. He has also been on clopidogrel for
ischaemic heart disease having had one episode on acute
Table 1 Perioperative data of patients having surgery without complications
Age of
patient
Type of surgery PMH/Reason for clopidogrel therapy Preoperative
Hb
Postoperative
Hb
80 Dynamic hip screw Right carotid bruit, anaemic and ischaemic heart disease 14.1 13.3
83 Thompsons
hemiarthroplasty
CVA, hyperlipidaemia and allergic to aspirin 14.6 12.6
79 Dynamic hip screw Hypertension, ischaemic heart disease, GORD and CVA 12.4 12.9
80 Thompsons
hemiarthroplasty
Hypertension, ischaemic heart disease 12.2 10.1
CVA: cerebrovascular accident; GORD: gastroesophageal reflux disease.
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included diabetes and hypertension. A cemented Thompsons
hemiarthroplasty was carried out by an experienced surgeon
with no excessive intraoperative bleeding.
Pre and postoperative haemoglobin were 14.6 and 13.0,
respectively. Postoperative X-rays were satisfactory, and he
was mobilised full weight bearing. Wound inspection was
unremarkable four days post operatively. The patient made
rapid progress and was transferred to the rehabilitation ward
five days post operatively. When he was on the rehabilitation
ward, the patient developed urinary sepsis and Clostridium
Difficile infection. He was transferred to the high depen-
dency unit for invasive monitoring. A partial wound dehis-
cence was noted twelve days post operatively. An ultrasound
did not reveal any deep collection. A wound swab grew
Staphylococcus Aureus and he was started on Flucloxacillin.
The antibiotics had minimal clinical effects and he remained
unwell. He eventually underwent a Girdlestone procedure
eight weeks post hemiarthroplasty.
Discussion
This case series describe patients who all underwent hip
fracture surgery within two days of stopping clopidogrel.
There were no bleeding problems noted in theatre and none
needed blood products in the perioperative period. However,
one of them who also had diabetes had a wound dehiscence/
infection and eventually needed a Girdlestone procedure.
The risks and benefits of early surgery must therefore be
considered carefully after discussion with appropriate spe-
cialities. These are the first described cases in the orthopae-
dic literature of patients undergoing orthopaedic surgery two
days of stopping clopidogrel.
Clopidogrel and bleeding
After discussion with the haematologist, we were advised to
proceed with surgery after stopping the clopidogrel for two
days and having crossmatched blood and platelets in case of
major intraoperative haemorrhage. Clopidogrel has an active
metabolite, which remains in the system for at least 24 h and
waiting for two days allows any transfused platelets to exert
their haemostatic effects should a major bleed occur. This
approach has the theoretical advantage of avoiding a longer
delay to wait for the bone marrow to renew the platelet pool
and hence allowing early surgery.
A meta-analysis of antiplatelets and bleeding in 2004
showed that low dose aspirin had the lowest bleeding com-plications and is not a contraindication to emergency surgery.
Data about the new antiplatelets such as clopidogrel is
scantier. There are anecdotal reports of increased bleeding
noted in patients on chronic clopidogrel therapy in different
surgical specialities.3,11 The cardiothoracic literature sug-
gests that clopidogrel is associated with increased bleeding
(blood products requirements, chest and mediastinal
drainage) in coronary artery bypass graft (CABG)
patients.1,4,7,12,19—21 However, these patients are often on
heparin and multiple high dose antiplatelet therapy and may
be more prone to bleeding. Bone and joint surgery is also
intrinsically different from most other surgical specialities as
it is difficult to achieve adequate haemostasis from cut bones
ends.
Aprotinin given intra operatively has been shown to
reduce postoperative bleeding and the number of transfu-
sions in patients undergoing CABG19 and in major orthopaedic
surgery.10 This may be a promising strategy that needs to be
explored in further randomised controlled trials.
Clopidogrel and vascular events
There are studies suggesting that clopidogrel is superior to
aspirin in prevention of ischaemic events and that dual
antiplatelet therapy may confer additional benefits.5,6,8 In
the UK, the National Institute for Health and Clinical Excel-
lence advocates the lifelong use of clopidogrel for the pre-
vention of occlusive vascular events, but not as a first line
agent. This includes treatment of stroke, peripheral vascular
disease, non-STsegment elevation acute coronary syndrome,
patients intolerant of aspirin and prevention of post myo-
cardial infarction atherothrombosis.16 Patients who have
coronary stents, especially those who are drug eluting,
should be on aspirin and clopidogrel for up to one year after
intervention.8 It is likely that with the greater life expec-
tancy and the increasing number of percutaneous coronary
interventions being carried out, more patients presenting to
the different surgical specialities will be on clopidogrel.
Clopidogrel and early surgery
The optimum timing of emergency surgery in trauma
patients on clopidogrel is not yet clear. Very often patients
admitted on a trauma unit need prompt fixation of their
fractures to enable early mobilisation and avoid complica-
tions. A delay in neck of femur fracture surgery has been
shown to be associated with worst outcomes as well as
increasing in hospital stay.2,15,17,18,22 Severe bleeding,
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life threatening. The number of proximal femur fractures in
the UK is expected to reach 70,000/year in 20109 and an
increasing proportion of them are going to be on antiplate-
let agent(s).
Conclusions
This case series and review of the literature shows that
clopidogrel may be associated with significant bleeding which
is not immediately apparent. The traditional delay of five to
seven days for hip fracture surgery may, however, be overtly
conservative, especially weighing against the potential med-
ical complications of delayed surgery. In the absence of clear
national guidelines, a multidisciplinary team approach invol-
ving the surgeon, anaesthetist, cardiologist and orthogeria-
trician is mandatory. Further controlled trials are needed to
guide best practice in this complex and increasingly common
problem.
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